Sequoia invests in Chinese AI drug startup

AI and pharmaceuticals are two of the hottest sectors in China right now. Sequoia's investment in DIP covers both of them.

Sequoia Capital China completed almost $15 million Series B investment in Beijing-based Deep Intelligent Pharma DIP, a Chinese startup that provides artificial intelligence AI technology for drug development, on September 28, though it was not announced until October 9.

DIP develops AI technologies throughout the whole drug RD process and most recently released an AI system that monitors adverse reactions to drugs a fresh application for AI use in the medical field. It means that the drug development process can be fully monitored from its early status to after-sales.

This is a new area for Chinese AI companies that has much scope for...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222